Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Caribou Biosciences Inc.

Generation Essentials Group, Phio Pharmaceuticals, and Caribou Biosciences are the 3&nbsp;Penny Stocks&nbsp;to watch on November 4, 2025, based on&...

3 Penny Stocks to Watch Now, 11/4/25

Caribou Biosciences, Inc. (($CRBU)) announced an update on their ongoing clinical study. Caribou Biosciences, Inc. is conducting a long-term follow...

Current Quarter	$-0.33	Next Quarter	$NA
Current Year	$-1.39	Next Year	$-1.47
QoQ Growth	NaN%	YoY Growth	-5.8%
3Y EPS CAGR	+7.9%	Target Price	$9.88
Consensus	Buy	Upside	+464.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRBU	$1.75	0.00%	1.19M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRBU	$1.75	0%	1.19M
3
4
5
6

CRBU

CRBU

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Caribou Biosciences Inc. Data in Excel

Get Caribou Biosciences Inc. Data in Excel